Alzamend Neuro, Inc. (ALZN) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
3500 LENOX RD. NE ATLANTA, GA 30326 |
| State of Incorp. | DE |
| Fiscal Year End | April 30 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) (USD)Annual | Quarterly
| 4/30/2025 Q4 | 1/31/2025 Q3 | 10/31/2024 Q2 | 7/31/2024 Q1 | 4/30/2024 Q4 | 1/31/2024 Q3 | 10/31/2023 Q2 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 3,358,135 | 4,093,073 | 1,193,950 | 376,048 | 282,867 | 200,079 | |||
| Cash and cash equivalent | 3,358,135 | 4,093,073 | 1,193,950 | 376,048 | 282,867 | 200,079 | |||
| Prepaid expense | 116,277 | 182,758 | 222,241 | 79,194 | 161,143 | 255,591 | |||
| Other undisclosed current assets | 472,931 | 490,911 | 149,595 | 326,211 | |||||
| Total current assets: | 3,947,343 | 4,766,742 | 1,416,191 | 455,242 | 593,605 | 781,881 | |||
| Noncurrent Assets | |||||||||
| Property, plant and equipment | 228,291 | 240,976 | 253,661 | 176,346 | 189,031 | 201,716 | |||
| Total noncurrent assets: | 228,291 | 240,976 | 253,661 | 176,346 | 189,031 | 201,716 | |||
| TOTAL ASSETS: | 4,175,634 | 5,007,718 | 1,669,852 | 631,588 | 782,636 | 983,597 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 725,851 | 1,254,750 | 2,882,171 | 2,925,059 | 3,826,457 | 3,666,090 | |||
| Accounts payable | 725,851 | 1,254,750 | 2,882,171 | 2,925,059 | 3,826,457 | 3,666,090 | |||
| Debt | 300,714 | ||||||||
| Total current liabilities: | 725,851 | 1,254,750 | 2,882,171 | 3,225,773 | 3,826,457 | 3,666,090 | |||
| Noncurrent Liabilities | |||||||||
| Liabilities, other than long-term debt | 742,263 | ||||||||
| Accounts payable and accrued liabilities | 742,263 | ||||||||
| Total noncurrent liabilities: | 742,263 | ||||||||
| Total liabilities: | 725,851 | 1,254,750 | 2,882,171 | 3,225,773 | 4,568,720 | 3,666,090 | |||
| Equity | |||||||||
| Equity, attributable to parent, including: | 3,449,783 | 3,752,968 | (1,212,319) | (2,594,185) | (4,263,821) | (2,682,493) | |||
| Common stock | 580 | 523 | 86 | 69 | 662 | 647 | |||
| Additional paid in capital | 60,845,019 | 60,162,478 | 53,782,414 | 51,426,154 | 48,974,396 | 62,699,614 | |||
| Accumulated deficit | (57,395,816) | (56,410,033) | (54,994,819) | (54,020,408) | (53,168,879) | (50,506,461) | |||
| Stockholders' equity note, subscriptions receivable | (70,000) | ||||||||
| Other undisclosed equity, attributable to parent | (14,876,293) | ||||||||
| Total equity: | 3,449,783 | 3,752,968 | (1,212,319) | (2,594,185) | (4,263,821) | (2,682,493) | |||
| Other undisclosed liabilities and equity | 477,737 | ||||||||
| TOTAL LIABILITIES AND EQUITY: | 4,175,634 | 5,007,718 | 1,669,852 | 631,588 | 782,636 | 983,597 | |||
Income Statement (P&L) (USD)Annual | Quarterly
| 4/30/2025 Q4 | 1/31/2025 Q3 | 10/31/2024 Q2 | 7/31/2024 Q1 | 4/30/2024 Q4 | 1/31/2024 Q3 | 10/31/2023 Q2 | ||
|---|---|---|---|---|---|---|---|---|
| Operating expenses | (1,037,415) | (1,358,068) | (962,405) | (850,064) | (2,659,930) | (2,901,722) | ||
| Operating loss: | (1,037,415) | (1,358,068) | (962,405) | (850,064) | (2,659,930) | (2,901,722) | ||
| Nonoperating expense | (2,019) | (3,495) | (12,006) | (1,465) | (2,488) | (4,311) | ||
| Interest and debt expense | (2,488) | (4,311) | ||||||
| Other undisclosed income from continuing operations before equity method investments, income taxes | 8,636 | |||||||
| Loss from continuing operations: | (1,039,434) | (1,361,563) | (974,411) | (842,893) | (2,664,906) | (2,910,344) | ||
| Other undisclosed net income | 1,974,411 | 1,642,893 | 5,364,906 | |||||
| Net income (loss): | (1,039,434) | (1,361,563) | 1,000,000 | 800,000 | 2,700,000 | (2,910,344) | ||
| Other undisclosed net income (loss) attributable to parent | (53,651) | (1,974,411) | (1,651,529) | (5,362,418) | 4,311 | |||
| Net loss available to common stockholders, basic: | (1,039,434) | (1,415,214) | (974,411) | (851,529) | (2,662,418) | (2,906,033) | ||
| Other undisclosed net income available to common stockholders, diluted | 2,039,434 | 2,815,214 | ||||||
| Net income (loss) available to common stockholders, diluted: | 1,000,000 | 1,400,000 | (974,411) | (851,529) | (2,662,418) | (2,906,033) | ||
Comprehensive Income (USD)Annual | Quarterly
| 4/30/2025 Q4 | 1/31/2025 Q3 | 10/31/2024 Q2 | 7/31/2024 Q1 | 4/30/2024 Q4 | 1/31/2024 Q3 | 10/31/2023 Q2 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | (1,039,434) | (1,361,563) | 1,000,000 | 800,000 | 2,700,000 | (2,910,344) | ||
| Comprehensive income (loss), net of tax, attributable to parent: | (1,039,434) | (1,361,563) | 1,000,000 | 800,000 | 2,700,000 | (2,910,344) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.